These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. Yamamoto K; Burnett JC; Jougasaki M; Nishimura RA; Bailey KR; Saito Y; Nakao K; Redfield MM Hypertension; 1996 Dec; 28(6):988-94. PubMed ID: 8952587 [TBL] [Abstract][Full Text] [Related]
3. Comparison of atrial natriuretic peptide B-type natriuretic peptide, and N-terminal proatrial natriuretic peptide as indicators of left ventricular systolic dysfunction. Davidson NC; Naas AA; Hanson JK; Kennedy NS; Coutie WJ; Struthers AD Am J Cardiol; 1996 Apr; 77(10):828-31. PubMed ID: 8623734 [TBL] [Abstract][Full Text] [Related]
4. Natriuretic peptides and the prevalence of congestive heart failure in patients with pacemakers. Gwechenberger M; Huelsmann M; Graf S; Berger R; Bonderman D; Stanek B; Rauscha F; Pacher R Eur J Clin Invest; 2004 Dec; 34(12):811-7. PubMed ID: 15606723 [TBL] [Abstract][Full Text] [Related]
5. Natriuretic peptides and cyclic guanosine 3',5'-monophosphate in asymptomatic and symptomatic left ventricular dysfunction. Friedl W; Mair J; Thomas S; Pichler M; Puschendorf B Heart; 1996 Aug; 76(2):129-36. PubMed ID: 8795474 [TBL] [Abstract][Full Text] [Related]
6. Atrial natriuretic peptide ANP(1-98) and ANP(99-126) in patients with severe chronic congestive heart failure: relation to echocardiographic measurements. A subgroup analysis from the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). Eriksson SV; Caidahl K; Hall C; Eneroth P; Kjekshus J; Offstad J; Swedberg K J Card Fail; 1995 Mar; 1(2):109-16. PubMed ID: 9420640 [TBL] [Abstract][Full Text] [Related]
7. Plasma neuro-endocrine activity in very elderly subjects and patients with and without heart failure. Dutka DP; Olivotto I; Ward S; Nihoyannopoulos P; al-Subaili M; Oakley CM; Impallomeni M; Cleland JG Eur Heart J; 1995 Sep; 16(9):1223-30. PubMed ID: 8582385 [TBL] [Abstract][Full Text] [Related]
8. Natriuretic peptides as markers of cardiotoxicity during doxorubicin treatment for non-Hodgkin's lymphoma. Nousiainen T; Jantunen E; Vanninen E; Remes J; Vuolteenaho O; Hartikainen J Eur J Haematol; 1999 Feb; 62(2):135-41. PubMed ID: 10052718 [TBL] [Abstract][Full Text] [Related]
9. Hemodynamic correlates of atrial natriuretic peptide concentration in unselected patients with heart disease of different etiologies. La Vecchia L; Fortunato A; Varotto L; Bonanno C; Paccanaro M; Ometto R; Vincenzi M G Ital Cardiol; 1998 Dec; 28(12):1363-71. PubMed ID: 9887389 [TBL] [Abstract][Full Text] [Related]
10. Circulating levels of cardiac natriuretic peptides (ANP and BNP) measured by highly sensitive and specific immunoradiometric assays in normal subjects and in patients with different degrees of heart failure. Clerico A; Iervasi G; Del Chicca MG; Emdin M; Maffei S; Nannipieri M; Sabatino L; Forini F; Manfredi C; Donato L J Endocrinol Invest; 1998 Mar; 21(3):170-9. PubMed ID: 9591213 [TBL] [Abstract][Full Text] [Related]
11. Usefulness of the brain natriuretic peptide to atrial natriuretic peptide ratio in determining the severity of mitral regurgitation. Shimamoto K; Kusumoto M; Sakai R; Watanabe H; Ihara S; Koike N; Kawana M Can J Cardiol; 2007 Mar; 23(4):295-300. PubMed ID: 17380223 [TBL] [Abstract][Full Text] [Related]
12. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Cowie MR; Struthers AD; Wood DA; Coats AJ; Thompson SG; Poole-Wilson PA; Sutton GC Lancet; 1997 Nov; 350(9088):1349-53. PubMed ID: 9365448 [TBL] [Abstract][Full Text] [Related]
13. Circulating N-terminal pro-atrial natriuretic peptide is an independent predictor of left ventricular hypertrophy in the general population. The Tromsø Study. Schirmer H; Omland T Eur Heart J; 1999 May; 20(10):755-63. PubMed ID: 10329067 [TBL] [Abstract][Full Text] [Related]
15. Longstanding atrial fibrillation causes depletion of atrial natriuretic peptide in patients with advanced congestive heart failure. van den Berg MP; Tjeerdsma G; Jan de Kam P; Boomsma F; Crijns HJ; van Veldhuisen DJ Eur J Heart Fail; 2002 Jun; 4(3):255-62. PubMed ID: 12034149 [TBL] [Abstract][Full Text] [Related]
16. [Acute changes in the hemodynamic profile and circulating levels of atrial natriuretic peptide induced by dobutamine in severe heart failure]. La Vecchia L; Bottero M; Centofante P; Bedogni F; Ometto R; Cera A; Fortunato A G Ital Cardiol; 1996 Aug; 26(8):863-74. PubMed ID: 9005168 [TBL] [Abstract][Full Text] [Related]
18. Reference ranges for natriuretic peptides for diagnostic use are dependent on age, gender and heart rate. Loke I; Squire IB; Davies JE; Ng LL Eur J Heart Fail; 2003 Oct; 5(5):599-606. PubMed ID: 14607197 [TBL] [Abstract][Full Text] [Related]
19. Plasma concentration of atrial natriuretic peptide is related to the duration of atrial fibrillation in patients with advanced heart failure. Wozakowska-Kapłon B; Opolski G; Janion M; Kosior D Kardiol Pol; 2004 Dec; 61(12):513-21; discussion 522. PubMed ID: 15815752 [TBL] [Abstract][Full Text] [Related]
20. BNP and ANP as diagnostic and predictive markers in heart failure with left ventricular systolic dysfunction. Falcão LM; Pinto F; Ravara L; van Zwieten PA J Renin Angiotensin Aldosterone Syst; 2004 Sep; 5(3):121-9. PubMed ID: 15526247 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]